Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus (Match-101)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Mitiglinide
Acarbose
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Mitiglinide, Acarbose, Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Subjects aged between 18 and 70, regardless of gender
- Subjects with type-2 diabetes mellitus diagnosed according to 1999 WHO criteria within 5 years
- Subjects who had not received insulin secretagogues, insulin sensitizers, incretin mimetics or alpha-glucosidase inhibitors
- Subjects whose fasting blood glucose [FBG] between7.0 and10.0 mmol/L and HbA1c ratio is between 7.0% and 10.0%
Note: Incretin mimetics contain glucagon-like peptide 1 (GLP-1) receptor agonist (including GLP-1 analogues) and dipeptidyl peptidase 4 inhibitors.
Exclusion Criteria:
- Subjects with abnormal hepatic function whose aspartate transaminase (AST) and alanine transaminase (ALT) are 2 times higher than the upper limits of normal (ULN)
- Subjects with renal disfunction whose plasma creatinine concentration are more than 1.1 ULN or positive urine protein
- Subjects with severe heart disease, liver diseases, kidney disease and other serious organic disease
- Subjects who have chronic intestinal diseases associated with marked disorders of digestion or absorption and may deteriorate as a result of increased gas formation in the intestine (like Gastrocardiac Syndrome, severe hernia, intestinal obstruction, intestinal ulcer and intestinal surgery)
- Subjects with endocrine system diseases such as hyperthyroidism and cushing's syndrome etc.
- Subject is contraindicated or hypersensitivity to both experimental drugs or comparator drugs
- Subjects who participated in other clinical studies as subjects within 3 months before this study
- Female subjects who have been pregnant , lactating or without contraception in childbearing potential
- Subjects judged unfit for this study by investigators
Sites / Locations
- The First People's Hospital of Changzhou
- The Second People's Hospital of Huai'an
- Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University
- Xuzhou Central Hospital
- Yancheng City No.1 People's Hospital
- Zhenjiang First People's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Mitiglinide
Acarbose
Arm Description
Mitiglinide 10 mg three times a day, orally, for 12 weeks
Acarbose 50 mg three times a day, orally, for 12 weeks
Outcomes
Primary Outcome Measures
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
Secondary Outcome Measures
the change from baseline to the end of treatment in fasting blood glucose (FBG), postprandial blood glucose (PBG)
Number of Participants with Serious and Non-Serious Adverse Events
Adverse events will be collected and followed in order to evaluate safety and tolerability
the change from baseline to the end of treatment in Diabetes Quality of Life
measured by Diabetes specific Quality of Life scale (DSQL) at baseline and 12 weeks
Treatment compliance
Diabetes Treatment Satisfaction
measured by Diabetes Treatment Satisfaction Questionnaire (DTSQs) at 12 weeks
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02143765
Brief Title
Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus
Acronym
Match-101
Official Title
An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhongda Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Mitiglinide, a benzylsuccinic acid derivative, exerts selective action on the ATP-dependent K (KATP) channel of pancreatic β-cells and reportedly possesses a stronger affinity to the channel compared with other insulinotropic sulphonylurea receptor ligands, namely repaglinide and nateglinide. Preprandial administration of mitiglinide efficiently reduces postprandial hyperglycemia and improves overall glycemic control.
This was a 12-week, open, randomized study for comparing Mitiglinide versus Acarbose. The purpose of this study is to evaluate the efficacy and safety of Mitiglinide vs Acarbose in patients with type 2 diabetes mellitus.
Detailed Description
Group I (Mitiglinide): Mitiglinide 10 mg three times a day, orally, for 12 weeks Group II (Acarbose): Acarbose 50 mg three times a day, orally, for 12 weeks Total subjects: 248, randomized to 2 groups at ratio of 1:1.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Mitiglinide, Acarbose, Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
248 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mitiglinide
Arm Type
Experimental
Arm Description
Mitiglinide 10 mg three times a day, orally, for 12 weeks
Arm Title
Acarbose
Arm Type
Active Comparator
Arm Description
Acarbose 50 mg three times a day, orally, for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Mitiglinide
Other Intervention Name(s)
FADI
Intervention Description
three times a day, orally, for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Acarbose
Other Intervention Name(s)
PRECOSE
Intervention Description
three times a day, orally, for 12 weeks
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
Time Frame
Baseline and Week 12
Secondary Outcome Measure Information:
Title
the change from baseline to the end of treatment in fasting blood glucose (FBG), postprandial blood glucose (PBG)
Time Frame
Baseline, 4 weeks, 8 weeks, 12 weeks
Title
Number of Participants with Serious and Non-Serious Adverse Events
Description
Adverse events will be collected and followed in order to evaluate safety and tolerability
Time Frame
up to 12 weeks
Title
the change from baseline to the end of treatment in Diabetes Quality of Life
Description
measured by Diabetes specific Quality of Life scale (DSQL) at baseline and 12 weeks
Time Frame
baseline and 12 weeks
Title
Treatment compliance
Time Frame
up to 12 weeks
Title
Diabetes Treatment Satisfaction
Description
measured by Diabetes Treatment Satisfaction Questionnaire (DTSQs) at 12 weeks
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects aged between 18 and 70, regardless of gender
Subjects with type-2 diabetes mellitus diagnosed according to 1999 WHO criteria within 5 years
Subjects who had not received insulin secretagogues, insulin sensitizers, incretin mimetics or alpha-glucosidase inhibitors
Subjects whose fasting blood glucose [FBG] between7.0 and10.0 mmol/L and HbA1c ratio is between 7.0% and 10.0%
Note: Incretin mimetics contain glucagon-like peptide 1 (GLP-1) receptor agonist (including GLP-1 analogues) and dipeptidyl peptidase 4 inhibitors.
Exclusion Criteria:
Subjects with abnormal hepatic function whose aspartate transaminase (AST) and alanine transaminase (ALT) are 2 times higher than the upper limits of normal (ULN)
Subjects with renal disfunction whose plasma creatinine concentration are more than 1.1 ULN or positive urine protein
Subjects with severe heart disease, liver diseases, kidney disease and other serious organic disease
Subjects who have chronic intestinal diseases associated with marked disorders of digestion or absorption and may deteriorate as a result of increased gas formation in the intestine (like Gastrocardiac Syndrome, severe hernia, intestinal obstruction, intestinal ulcer and intestinal surgery)
Subjects with endocrine system diseases such as hyperthyroidism and cushing's syndrome etc.
Subject is contraindicated or hypersensitivity to both experimental drugs or comparator drugs
Subjects who participated in other clinical studies as subjects within 3 months before this study
Female subjects who have been pregnant , lactating or without contraception in childbearing potential
Subjects judged unfit for this study by investigators
Facility Information:
Facility Name
The First People's Hospital of Changzhou
City
Changzhou
State/Province
Jiangsu
Country
China
Facility Name
The Second People's Hospital of Huai'an
City
Huai'an
State/Province
Jiangsu
Country
China
Facility Name
Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University
City
Nanjing
State/Province
Jiangsu
Country
China
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
Country
China
Facility Name
Yancheng City No.1 People's Hospital
City
Yancheng
State/Province
Jiangsu
Country
China
Facility Name
Zhenjiang First People's Hospital
City
Zhenjiang
State/Province
Jiangsu
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
Citation
LV Xiaofeng. Clinical study on efficacy and safety of mitiglinide on type 2 diabetes mellitus. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2):175-179.
Results Reference
result
PubMed Identifier
23602502
Citation
Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther. 2013 Jun;35(6):880-99. doi: 10.1016/j.clinthera.2013.03.020. Epub 2013 Apr 18.
Results Reference
result
Learn more about this trial
Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs